Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 2, 2007, Pages 193-197

  Xu, Gelin ^a   Liu, Xinfeng ^a   Zhu, Wusheng ^a   Yin, Qin ^a   Zhang, Renliang ^a   Fan, Xiaobing ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Batroxobin; Fibrinogen; Prevention; Risk factors; Stroke; Transient ischemic attack

Indexed keywords

BATROXOBIN; FIBRINOGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BRAIN HEMORRHAGE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEASIBILITY STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN DEFECT; FOLLOW UP; HEART FAILURE; HUMAN; HYPERFIBRINOGENENMIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; SAFETY; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 33846912015     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328040c0f2     Document Type: Article

References (19)

1. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-505.
2. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799-1809.
3. Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005; 36:2143-2147.
4. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004; 35:2300-2305.
5. Liu M, Counsell C, Zhao XL, Wardlaw J. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database Syst Rev 2003; 3:CD000091.
6. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000; 283:2395-2403.
7. Nuber R. Ancrod in acute ischaemic stroke: status of the European ESTAT trial after 1000 patients [abstract]. Cerebrovasc Dis 2000; 10 (Suppl 2):83.
8. Stroke - 1989: recommendations on stroke prevention, diagnosis, and therapy: report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989; 20:1407-1431.
9. Rao ML. Chinese National Guidelines for Prevention and Management of Ischemic Cerebrovascular Diseases [in Chinese]. Zhongfeng Yu Shenjing Xitong Jibing Zazhi 2005; 22:388-393.
10. Kutake K, Fujimaki M, Nagasawa H, Kato M. Clinico-pharmacological observations of batroxobin (Defibrase1) administered to normal human adults. Acta Haematol Jpn 1981; 44:1178-1194.
11. The Cooperative Group for Reassessment of Defibrase. Reassessment of defibrase in treatment of acute cerebral infarction: a multicenter, randomized, double-blind, placebo-controlled trial. Chin Med Sci J 2005; 20:151-158.
12. Hossmann V, Heiss WD, Bewermeyer H, Wiedemann G. Controlled trial of ancrod in ischemic stroke. Arch Neurol 1983; 40:803-808.
13. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989; 111:1010-1022.
14. Tomita K, Muso E, Tamura T, Kawai C. The effect of hypofibrinogenemia with batroxobin on rat Masugi nephritis. Jpn Circ J 1982; 46:577-582.
15. Sapru RP, Moza AK, Kumar M, Ganguly NK. Antibodies to arvin following prolonged intravenous therapy. Thromb Res 1975; 7:635-641.
16. Nishimura H, Takahashi K, Sakurai K, Fujinuma K, Imamura Y, Ooba M, et al. Modification of batroxobin with activated polyethylene glycol: reduction of binding ability towards anti-batroxobin antibody and retention of defibrinogenation activity in circulation of preimmunized dogs. Life Sci 1983; 33:1467-1473.
17. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258:1183-1186.
18. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E, et al. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med 2001; 111:457-463.
19. Behar S. Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention. Blood Coagul Fibrinolysis 1999; 10 (Suppl 1):S41-S43.